ArticleCardiovascular diabetology2025
Left ventricular ejection fraction reserve and its association with myocardial perfusion, coronary calcification, and strain in type 2 diabetes without overt cardiovascular disease.
Article in Cardiovascular diabetology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundType 2 diabetes (T2D) is a major risk factor for cardiovascular disease (CVD), but the relationships between myocardial function, microvascular function, and atherosclerotic burden remain underexplored in asymptomatic individuals. This study investigates the associations between left ventricular ejection fraction (LVEF)-reserve, myocardial flow reserve (MFR), perfusion defects, coronary artery calcium score (CACS), and global longitudinal strain (GLS) in individuals with T2D but without overt CVD.
methodsCross-sectional analysis of 871 individuals with T2D without overt CVD, recruited between 2020 and 2023. All underwent cardiac 82-Rubidium PET/CT to assess LVEF-reserve, MFR, perfusion defects, and CACS. GLS was measured using echocardiography. Associations were examined using linear regression adjusted for cardiovascular risk factors and cardiometabolic therapies.
resultsMean (SD) age was 64.9 (± 9.0) years, diabetes duration was 13.9 (± 8.4) years, and 262 (30%) were women. Higher MFR was associated with higher LVEF-reserve (β = 1.63, 95% CI: 1.16 to 2.10, p < 0.001). Individuals with CACS > 300 had lower LVEF-reserve than those with CACS ≤ 300 (β = - 1.25, 95% CI: - 1.97 to - 0.53, p < 0.001). Presence of Perfusion defects were associated with lower LVEF-reserve (β = - 1.49, 95% CI: - 2.23 to - 0.75, p < 0.001). LVEF-reserve was not associated with GLS (p = 0.23). Sensitivity analysis excluding 248 participants with perfusion defects confirmed the association between MFR and LVEF-reserve (β = 1.45 (95% CI: 0.92, 1.97), p < 0.001).
conclusionsIn individuals with T2D without overt CVD, lower MFR, presence of perfusion defects, and CACS > 300 were associated with lower LVEF-reserve. Underscoring a potential role of microvascular dysfunction in subclinical systolic impairment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.